These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 10898340

  • 1. Cellular and molecular mechanisms of action of bisphosphonates.
    Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC.
    Cancer; 2000 Jun 15; 88(12 Suppl):2961-78. PubMed ID: 10898340
    [Abstract] [Full Text] [Related]

  • 2. New insights into the molecular mechanisms of action of bisphosphonates.
    Rogers MJ.
    Curr Pharm Des; 2003 Jun 15; 9(32):2643-58. PubMed ID: 14529538
    [Abstract] [Full Text] [Related]

  • 3. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ, Thompson K, Gordon S, Rogers MJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG, Rogers MJ.
    Bone; 1999 Jul 15; 25(1):97-106. PubMed ID: 10423031
    [Abstract] [Full Text] [Related]

  • 5. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
    Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ.
    J Bone Miner Res; 1998 Apr 15; 13(4):581-9. PubMed ID: 9556058
    [Abstract] [Full Text] [Related]

  • 6. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.
    Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP.
    Curr Pharm Des; 2010 Apr 15; 16(27):2950-60. PubMed ID: 20722616
    [Abstract] [Full Text] [Related]

  • 7. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ.
    J Bone Miner Res; 2000 Aug 15; 15(8):1467-76. PubMed ID: 10934645
    [Abstract] [Full Text] [Related]

  • 8. Bisphosphonates: the first 40 years.
    Russell RG.
    Bone; 2011 Jul 15; 49(1):2-19. PubMed ID: 21555003
    [Abstract] [Full Text] [Related]

  • 9. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb 15; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 10. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton.
    Rogers MJ, Mönkkönen J, Munoz MA.
    Bone; 2020 Oct 15; 139():115493. PubMed ID: 32569873
    [Abstract] [Full Text] [Related]

  • 11. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
    Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ.
    Bone; 2001 May 15; 28(5):465-73. PubMed ID: 11344045
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
    Van Beek ER, Löwik CW, Papapoulos SE.
    Bone; 2002 Jan 15; 30(1):64-70. PubMed ID: 11792566
    [Abstract] [Full Text] [Related]

  • 13. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
    David P, Nguyen H, Barbier A, Baron R.
    J Bone Miner Res; 1996 Oct 15; 11(10):1498-507. PubMed ID: 8889850
    [Abstract] [Full Text] [Related]

  • 14. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.
    Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ.
    J Bone Miner Res; 1998 Nov 15; 13(11):1668-78. PubMed ID: 9797474
    [Abstract] [Full Text] [Related]

  • 15. Effects of two novel bisphosphonates on bone cells in vitro.
    Evans CE, Braidman IP.
    Bone Miner; 1994 Aug 15; 26(2):95-107. PubMed ID: 7994190
    [Abstract] [Full Text] [Related]

  • 16. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG.
    Bone; 2011 Jul 15; 49(1):20-33. PubMed ID: 21497677
    [Abstract] [Full Text] [Related]

  • 17. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E, Löwik C, van der Pluijm G, Papapoulos S.
    J Bone Miner Res; 1999 May 15; 14(5):722-9. PubMed ID: 10320520
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonates: mode of action and pharmacology.
    Russell RG.
    Pediatrics; 2007 Mar 15; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
    Li B, Ling Chau JF, Wang X, Leong WF.
    J Cell Biochem; 2011 May 15; 112(5):1229-42. PubMed ID: 21465521
    [Abstract] [Full Text] [Related]

  • 20. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.
    Rogers MJ.
    Calcif Tissue Int; 2004 Dec 15; 75(6):451-61. PubMed ID: 15332174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.